,Name,SMILES,IC50_PAI1_nM,Status,Developer,Mechanism,Reference,Clinical_Stage,hERG_IC50_uM,Hepatotoxicity,Oral_Bioavailability_%,CYP_Inhibition,BBB_Permeability,LD50_rat_oral_mg_kg,Protein_Binding_%,Half_life_hours,IC50_PAI1_uM,Clinical_Notes
TM5441,TM5441,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)C(F)(F)F,6.4,Preclinical,University of Michigan,Allosteric inhibitor (blocks vitronectin binding),Izuhara et al. 2008 (PMID: 18635536),None,18.5,Low risk,52,2D6 (moderate),0.08,920,94,6.2,,
SK-216,SK-216,C1CN(CCN1C(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)OC)C,5.1,Preclinical,Seoul National University,Active site blocker (inhibits serpin-protease complex formation),Kim et al. 2016,None,22.3,Low risk,48,None significant,0.05,1050,91,5.8,,
TM5275,TM5275,,12.8,Preclinical,University of Michigan,Allosteric inhibitor (TM5441 derivative),Gorlatova et al. 2007,None,15.2,Low risk,45,2D6 (mild),0.09,850,92,7.1,,
PAI-039,PAI-039 (Tiplaxtinin),,,Phase II COMPLETED,Bristol-Myers Squibb,Oral PAI-1 inhibitor,NCT00801112,Phase II,28.0,No significant hepatotoxicity observed in Phase II,38,None,0.03,1200,88,8.5,9.0,Terminated - insufficient efficacy for cardiovascular endpoints (but SAFE)
